🇺🇸 FDA
Patent

US 11813257

Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors

granted A61KA61K31/4178A61K31/496

Quick answer

US patent 11813257 (Methods of treating erythropoietic protoporphyria, X-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors) held by Disc Medicine, Inc. expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Disc Medicine, Inc.
Grant date
Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
23
CPC classes
A61K, A61K31/4178, A61K31/496, A61K31/69, A61K31/785